Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report)'s stock price gapped down before the market opened on Friday . The stock had previously closed at $2.56, but opened at $2.49. Tevogen Bio shares last traded at $2.95, with a volume of 13,727,006 shares traded.
Analyst Ratings Changes
Separately, Fundamental Research set a $4.20 price target on shares of Tevogen Bio and gave the company a "buy" rating in a research note on Friday, June 28th.
View Our Latest Report on TVGN
Tevogen Bio Price Performance
The firm has a 50 day moving average price of $0.72 and a two-hundred day moving average price of $0.87.
Insider Buying and Selling at Tevogen Bio
In other news, insider Neal Flomenberg sold 1,078,600 shares of the business's stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $1.62, for a total value of $1,747,332.00. Following the transaction, the insider now owns 4,254,302 shares in the company, valued at approximately $6,891,969.24. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 56.60% of the company's stock.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Tevogen Bio stock. Portland Global Advisors LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,782,209 shares of the company's stock, valued at approximately $21,683,000. Tevogen Bio accounts for about 3.0% of Portland Global Advisors LLC's investment portfolio, making the stock its 9th largest position. Portland Global Advisors LLC owned approximately 36.55% of Tevogen Bio at the end of the most recent quarter.
About Tevogen Bio
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Further Reading
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
